All News
Tuesday Nite Rheumatology Grand Rounds - Febrile Disorders
Dr. Jack Cush reviews the appproach to evaluating fever in adults suspected of having a rheumatic disease, Stills disease or autoinflammatory conditions.
Read ArticleRheumNow Podcast – Drive Them Crazy (4.17.20)
Dr. Jack Cush reviews the news, journal articles and new ACR COVID-19 guidelines from the past week on RheumNow.com.
COVID-19 Systemic Involvement
The presentations of the COVID-19 infection have been clearly chronicled with the worrisome onset of sore throat, dry cough, loss of smell and taste with fevers, myalgias, fatigue and the worrisome progression of pulmonary involvement in a minority. Lab findings may include a leukocytosis,
Read ArticleACR COVID-19 Guidance for Rheumatic Disease Patients
On April 11th, the ACR Board of Directors approved a COVID-19 guidance document written by an ACR task force charged with updating and clarifying recommendations for rheumatologists and rheumatic disease patient management during the current COVID-19 crisis.
Read ArticlePost 9/11 Autoimmune Disease Risk
The 9/11/01 terrorist attach on the World Trade Center (WTC) resulted in at least 2,977 fatalities, over 25,000 injuries, and caused at least $10 billion in infrastructure and property damage. Arthritis & Rheumatology reports that dust cloud exposure among responders and
Read ArticleRheumNow Podcast – Pandemic Numbers (4.3.20)
Dr. Jack Cush reviews the news on COVID-19 and FDA actions this past week. Be sure to check out:
Read ArticleGlobal Rheumatology Alliance Registry Will Study COVID-19
In the midst of a global pandemic of the 2019 Novel coronavirus acute respiratory disease (COVID-19), a small handful of Rheumatologists gathered on social media to collectively grapple with the impact of this virus on vulnerable populations with rheumatic disease.
The COVID-19 Global Rheumatology Registry
As the highly virulent SARS-CoV-2 spreads over the world, uncertainty and fear for our patients with rheumatic diseases mount.
Read ArticleEarlier Anakinra Initiation Warranted in Still's Disease
An Italian study examined the outcomes in adult onset Still's disease (AOSD) based on whether they received early or delayed treatment with anakinra (ANK).
A total of 141 AOSD patients were retrospectively studied.
Read ArticleRheumNow Podcast - Despite Corona (3.6.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
RheumNow Podcast- Half-Empty Flu (2.21.20)
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleTofacitinib Effective in Refractory Still's Disease
Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.
Read ArticleBSR Guidelines for Giant Cell Arteritis
NICE has commissioned an update to the 2010 British Society for Rheumatology guideline for the management of giant cell arteritis, and proposed a total of 19 recommendations for the diagnosis and treatment of GCA.
Read ArticleRheumNow Podcast- Best Biologics (2.7.20)
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleRheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleRheumNow Podcast- A Good First Impression (1.24.20)
Dr Jack Cush comments on this week's journal articles, reviews and studies.
Read ArticleQD Clinic - "Doc, When Can I Stop?"
QD Clinic - Lessons from the clinic. In this video: Patients stable on a biologic need guidance on when, and if, they can stop their biologic.
Read ArticleACR 2018 - Day 3 Report
Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included the PEXIVAS Study, ACR Reproductive Health Draft Guidelines, and a Proof of concept study
Read ArticleBest of 2019 - Methotrexate and the Risk of Lung Disease
Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.
Read ArticleA Role for SGLT2 Inhibition in Gout?
The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.
Read Article